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Hex-A deficiency leads to severe neurodegeneration, due to excessive storage of gangliosides in the central nervous system (CNS). Onset of symptoms depends on residual Hex-A activity, with symptoms starting in the first year of life in cases of complete enzyme deficiency. 2 To date, no effective treatment for TSD is available. 3 Allogeneic BMT has been used to treat patients with various lysosomal storage disorders. Successful transplantation provides metabolically competent haematopoietic cells in affected tissues, which may correct the enzyme deficiency. BMT is not effective when severe neurological symptoms are already present at the time of transplantation. 4 The effect of BMT in patients with TSD is unknown. Another approach for treating storage disorders is substrate reduction therapy. The experimental drug Nbutyldeoxynojirimycin (Zavesca s ) inhibits glucosyltransferase, the enzyme that catalyses the biosynthesis of gangliosides from ceramide. 5 In mice with TSD, Zavesca s markedly reduced ganglioside accumulation and prevented neuropathology. 6 Here, we describe the biochemical and clinical effects of allogeneic BMT followed by treatment with Zavesca s in TSD. The patient was diagnosed with TSD, after we diagnosed TSD in her older sister. Our patient was asymptomatic except for two episodes of seizures shortly before BMT. After informed consent was given, BMT was performed at the age of 3 years and 10 months. Pre-BMT, neurological and ophthalmological examinations and electroencephalography (EEG) were normal, cerebral MR imaging (MRI) showed mild, nonspecific periventricular signal abnormalities ( Figure 1a ) and neuropsychological testing showed normal development. After conditioning with busulphan 5 mg/kg daily for 4 days and rabbit antithymocyte globulin 5 mg/kg daily for 4 days, followed by cyclophosphamide 60 mg/kg for 4 days, she received bone marrow from an unrelated donor (T-cell depleted). GvHD prophylaxis consisted of cyclosporin A.
The post-BMT period was uneventful and rapid haematological recovery occurred. Hex-A activity levels in leucocytes increased directly after BMT, reaching normal values. Enzyme activity levels in plasma increased modestly (Table 1) . After 3 months, enzyme activity levels decreased and stabilised below normal levels suggesting mixed chimerism.
After BMT, seizures occurred, which responded well to valproate. Motor skills and speech gradually deteriorated during the first half-year after BMT. We found no explanation other than cyclosporin toxicity or progression of the underlying disease. After gradually lowering the dose of cyclosporin, speech improved remarkably. Cerebral MRI 6 months after BMT showed modest enlargement of the ventricular system and subarachnoidal spaces, reflecting cerebral atrophy. At that time, the EEG showed frequent epileptic discharges combined with diffuse background 
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s was given at a daily dosage of 7 mg/kg during 12 months. This, however, did not influence the deterioration.
BMT followed by substrate reduction therapy resulted in a rise in Hex-A but could not prevent neurological deterioration in our patient. This therapeutic regimen did not seem to influence the natural course of the disease beneficially. Owing to the wide clinical variability of subacute TSD, even within a family, it is too early to draw definite conclusions on the role of BMT in TSD.
Additionally, enzyme levels reached only in the heterozygous range, which may have influenced the poor longterm outcome. 
